Search details
1.
First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia.
N Engl J Med
; 388(19): 1739-1754, 2023 May 11.
Article
in English
| MEDLINE | ID: mdl-37163621
2.
Reassessing the Chronic Lymphocytic Leukemia International Prognostic Index in the era of targeted therapies.
Blood
; 2024 Apr 15.
Article
in English
| MEDLINE | ID: mdl-38620092
3.
Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial.
Blood
; 142(8): 687-699, 2023 08 24.
Article
in English
| MEDLINE | ID: mdl-37390310
4.
High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations.
Blood
; 142(5): 446-459, 2023 08 03.
Article
in English
| MEDLINE | ID: mdl-37172204
5.
Fixed-duration venetoclax plus obinutuzumab improves quality of life and geriatric impairments in FCR-unfit patients with CLL.
Blood
; 142(13): 1131-1142, 2023 09 28.
Article
in English
| MEDLINE | ID: mdl-37363833
6.
Activity of venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia: analysis of the VENICE-1 multicentre, open-label, single-arm, phase 3b trial.
Lancet Oncol
; 25(4): 463-473, 2024 Apr.
Article
in English
| MEDLINE | ID: mdl-38467131
7.
Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab.
Blood
; 140(8): 839-850, 2022 08 25.
Article
in English
| MEDLINE | ID: mdl-35605176
8.
Characterization of metabolic alterations of chronic lymphocytic leukemia in the lymph node microenvironment.
Blood
; 140(6): 630-643, 2022 08 11.
Article
in English
| MEDLINE | ID: mdl-35486832
9.
Electron transport chain and mTOR inhibition synergistically decrease CD40 signaling and counteract venetoclax resistance in chronic lymphocytic leukemia.
Haematologica
; 109(1): 151-162, 2024 Jan 01.
Article
in English
| MEDLINE | ID: mdl-37439352
10.
Hyperimmune Globulin for Severely Immunocompromised Patients Hospitalized With Coronavirus Disease 2019: A Randomized, Controlled Trial.
J Infect Dis
; 227(2): 206-210, 2023 01 11.
Article
in English
| MEDLINE | ID: mdl-35921542
11.
Fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial.
Lancet Oncol
; 24(12): 1423-1433, 2023 Dec.
Article
in English
| MEDLINE | ID: mdl-37944541
12.
Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL.
Blood
; 137(10): 1365-1376, 2021 03 11.
Article
in English
| MEDLINE | ID: mdl-32992344
13.
Inhibition of casein kinase 2 sensitizes mantle cell lymphoma to venetoclax through MCL-1 downregulation.
Haematologica
; 108(3): 797-810, 2023 03 01.
Article
in English
| MEDLINE | ID: mdl-36226498
14.
Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): primary analysis of an open-label, randomised, phase 2 trial.
Lancet Oncol
; 23(6): 818-828, 2022 06.
Article
in English
| MEDLINE | ID: mdl-35654052
15.
Human CXCR5+ PD-1+ CD8 T cells in healthy individuals and patients with hematologic malignancies.
Eur J Immunol
; 51(3): 703-713, 2021 03.
Article
in English
| MEDLINE | ID: mdl-33098668
16.
Changes in Bcl-2 members after ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL.
Blood
; 136(25): 2918-2926, 2020 12 17.
Article
in English
| MEDLINE | ID: mdl-32603412
17.
Obinutuzumab in the treatment of B-cell malignancies: a comprehensive review.
Future Oncol
; 18(26): 2943-2966, 2022 Aug.
Article
in English
| MEDLINE | ID: mdl-35856239
18.
The effect of a Clinical Decision Support System on the frequency of dose adjustments of anticancer drugs in case of renal or hepatic dysfunction.
J Oncol Pharm Pract
; 28(5): 1063-1069, 2022 Jul.
Article
in English
| MEDLINE | ID: mdl-34111993
19.
Inhibiting BTK in Chronic Lymphocytic Leukemia.
N Engl J Med
; 389(1): 83-86, 2023 Jul 06.
Article
in English
| MEDLINE | ID: mdl-37407007
20.
Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.
N Engl J Med
; 378(12): 1107-1120, 2018 Mar 22.
Article
in English
| MEDLINE | ID: mdl-29562156